Close Menu

NEW YORK (360Dx) – Ortho Clinical Diagnostics said today that its next-generation Vitros High Sensitivity Troponin I assay has been CE marked.

The test can be used to rapidly and accurately identify patients suffering from heart attacks, and to help identify low-risk patients who may be safely discharged, reducing both healthcare costs and resource burden on hospitals, Ortho said.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.